<DOC>
	<DOCNO>NCT00183092</DOCNO>
	<brief_summary>The purpose clinical trial determine effectiveness medication quinacrine survival sporadic Creutzfeldt-Jakob disease ( sCJD ) .</brief_summary>
	<brief_title>CJD ( Creutzfeldt-Jakob Disease ) Quinacrine Study</brief_title>
	<detailed_description>Creutzfeldt-Jakob disease ( CJD ) rapidly progressive , invariably fatal untreatable neurodegenerative disease mean duration eight month . Beyond debilitate cognitive motor deficit accompany CJD , difficulty treat behavioral mood disturbance rapidity course compound tragedy . Recent result experiment show , physiological concentration , anti-malarial drug quinacrine permanently clear abnormal prion protein cell culture . The demonstrated efficacy quinacrine cell culture , relative safety well know side-effects clinical setting , universal fatality CJD justify quinacrine immediate candidate treatment CJD . The purpose clinical trial determine efficacy medication quinacrine survival sporadic CJD ( sCJD ) . This accomplish bring approximately 60 patient probable definite sCJD approximately three year UCSF evaluation initiation randomize , double-blinded , placebo-controlled ( delayed treatment start ) treatment study quinacrine . Each patient 50:50 chance place quinacrine placebo upon study enrollment ; however , patient offer quinacrine two month . Prior study enrollment , patient comprehensive clinical assessment confirm diagnosis sCJD . Participants come UCSF initial evaluation , potential study enrollment , possible , return UCSF follow-up two twelve month . Patients receive telephone follow-up ( every 2 week first two month monthly thereafter ) local blood test monitor possible medication toxicity .</detailed_description>
	<mesh_term>Creutzfeldt-Jakob Syndrome</mesh_term>
	<mesh_term>Quinacrine</mesh_term>
	<criteria>Diagnosis probable definite sCJD : Definitebiopsy confirm sCJD ; Probablea progressive dementia either typical EEG typical MRI consistent sCJD , least two follow clinical feature : myoclonus , pyramidal extrapyramidal sign , visual symptom , cerebellar sign , akinetic mutism , focal high cortical neurologic sign ( e.g . neglect , apraxia , aphasia ) 18 year age old Able swallow Able follow simple onestep command Have brain MRI within 6 month EEG within 3 month rule etiology mass , stroke , nonconvulsive status epilepticus Consent autopsy event death study History significant lifethreatening disease , include : cancer ; endstage liver renal disease ; severe heart disease History disease require regular supportive care Liver disease Active alcoholism Bone marrow suppression Severe hypotension Severe psoriasis Poorly control diabetes Women pregnant breastfeed Men , woman childbearing age , practice reliable contraception Serious allergy quinacrine acridines Current recent use quinacrine ( within 6 month ) &lt; 18 year age Any contraindication take quinacrine Genetic form prion disease identify prior study enrollment Current use antiarrhythmic ( discretion investigator ) G6PD ( Glucose 6Phosphate Dehydrogenase ) deficiency ( discretion investigator )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>dementia</keyword>
	<keyword>spongiform encephalopathy</keyword>
	<keyword>nervous system disorder</keyword>
	<keyword>acridine</keyword>
	<keyword>prion</keyword>
	<keyword>neuropharmacologic agent</keyword>
</DOC>